|
Short-Seller wetten gegen Prothena
www.fiercebiotech.com/biotech/...are-disease-med-short-attack
Prothena hat in dieser Handelswoche ein neues 52W-Tief bei 35,78$ markiert.
Prothena meldet $150 million collaboration deal mit Celgene
www.investors.com/news/technology/...n-neurological-diseases/
Prothena floppt in Phase 2b Studie und stellt Phase 3 Studie von NEOD001 ein
ir.prothena.com/releasedetail.cfm?ReleaseID=1064584
ir.prothena.com/news-releases/...er-2019-financial-results-and
EcoR1 hält 23,6% an Prothena
www.sec.gov/Archives/edgar/data/1559053/...52/prothena13d.htm
"The Company expects its full year 2020 net cash burn from operating and investing activities to be $60-$76 million, and to end the year with approximately $310 million in cash, cash equivalents and restricted cash (midpoint). The estimated full year 2020 cash burn from operating and investing activities is primarily driven by an estimated net loss of $84-$106 million, which includes an estimated $23 million of non-cash shared-based compensation expense."
Prasinezumab Update
ir.prothena.com/news-releases/...udy-prasinezumab-prx002rg7935
Prasinezumab soll in die Phase 2b (Parkinson im Frühstudium) überführt werden, trotz des Phase2 "Flops"
endpts.com/...rkinsons-drug-into-late-stage-trial-a-60m-move/
Insider-Kauf im Februar
www.gurufocus.com/stock/PRTA/insider?search=prothena
68 Mio. $ Offering
ir.prothena.com/news-releases/...ic-offering-3500000-ordinary
60 Mio. $ Meilensteinzahlung von Roche
Durch die Dosierung des ersten Patienten in der Phase 2b PADOVA Studie von prasinezumab (frühe Parkinson-Krankheit) erreicht Prothena einen wichtigen klinischen Meilenstein.
ir.prothena.com/news-releases/...illion-milestone-roche-first
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
31 | News von heute | Lapismuc | Vassago | 08.01.24 16:40 |